Pharmaceutical Contract Manufacturing Global Market – Forecast To 2027
Globally Pharmaceutical markets are showing rapid growth and in coming years expected to evolve further in the field of research and development, manufacturing, and formulation due to rise in population, increase in chronic diseases like infectious diseases, oncology, cardiovascular disorders, rising healthcare expenditures, collaborations, mergers, and acquisitions. Pharmaceutical companies are increasing their dependence on contract manufacturing organizations due to lack of well-equipped manufacturing facilities, advanced technologies, high containment capabilities or though they have the facilities, due to insufficient time and to have backup manufacturing, pharmaceutical companies are outsourcing. This trend is favoring contract manufacturing service providers and is expected to increase the share in the pharmaceutical manufacturing market. Contract pharmaceutical manufacturing services are mainly focused on the manufacturing of Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF).
The pharmaceutical contract manufacturing global market is expected to reach $120,124.7 million by 2027 growing at a high single digit CAGR. Increased trend of outsourcing, high uptake of small molecules drugs across diverse therapeutics, patent expiration of small molecules, advanced technologies in API and FDF manufacturing, increasing deals and investments, increased demand for generic injectables, increasing incidence and prevalence of chronic diseases, and increase in geriatric population are some of the factors driving the market growth. However, contamination of pharmaceutical products (API and FDF), pricing pressure for pharmaceutical contract manufacturing, requirement of highly skilled technicians, increasing biologics approvals and adoption in disease management, stringent regulatory policies, and environmental concerns are some of the factors that are hindering pharmaceutical contract manufacturing global market growth. The pharmaceutical contract manufacturing global market is mainly segmented based on product, phase, application, and geography.
The pharmaceutical contract manufacturing market based on product is segmented into API manufacturing and FDF manufacturing. API manufacturing segment accounted for the largest share in 2020 and FDF manufacturing segment is the fastest growing segment and is expected to grow at high single digit CAGR from 2020 to 2027. The high profit margin for pharma contract manufacturers, shifting from API to FDF manufacturing by CMOs and CDMOs, rising demand for advanced dosage forms, and rising demand for generic drugs are some of the factors driving the growth of the FDF contract manufacturing market.
The API manufacturing market global market based on customer base is sub-segmented into Branded API manufacturing and Generic API manufacturing. The generic API manufacturing segment accounted for the largest revenue in 2020 and is expected to grow at high single digit CAGR from 2020 to 2027, due to the patent expiries of branded drugs, low cost of generic medicines.
The FDF manufacturing global market based on dosage form is further classified into solid dosage form, injectable dosage form, and semi-solid liquid and gaseous dosage form. Solid dosage form segment accounted for the largest revenue in 2020 due to changing consumer demands, advent and progress of newer dosage forms, and ever-evolving regulations. The injectable dosage form is the fastest-growing segment and is expected to grow at a low teen CAGR from 2020 to 2027 due to its direct infusion to the body, ease of administration, and onset of action of drugs is faster as compared to solid dosage forms. Hence it is suitable for emergency conditions. Among semi-solid, liquid, and gaseous dosage form, semisolids segment accounted for the largest revenue of in 2020 owing to the increased usage of semisolids such creams, lotions and gels due to increase in skin related diseases, and changing climatic conditions.
The solid dosage form market is further classified into tablets, capsules, and others such as powders and granules. Among these, tablets segment generated the largest revenue in 2020 owing to its ease of formulation techniques, manufacturing, and ease of administration to all the age groups.
Pharmaceutical contract manufacturing global market based on phase is segmented into commercial manufacturing and clinical manufacturing. Commercial manufacturing segment contributed to the largest revenue in 2020 due to huge demand for commercial API production, patent expiry, and increasing outsourcing of generic APIs. Whereas, clinical manufacturing segment is the fastest growing segment and is expected to grow at high single digit CAGR from 2020 to 2027 owing to a rise in demand for effective novel drugs with various therapeutic applications, rise in R&D investments for discovering new drugs coupled with the rising number of different types of chronic diseases.
The pharmaceutical contract manufacturing market by therapeutic applications is segmented into infectious diseases, oncology, cardiovascular disorders, central nervous system, pulmonary disorder, gastrointestinal disorder, endocrine disorders, metabolic disorders, genito-urinary disorders, musculoskeletal disorders, and others such as others such as ophthalmology, autoimmune diseases, ENT, dental, dermatology, and pain management. Among these applications, the infectious disease segment accounted for the largest revenue in 2020 because of the global-wide rapid spread of COVID-19 and increased incidence of other infectious diseases such as tuberculosis, HIV, pneumonia, influenza, hepatitis, and others. The oncology division is the fastest growing and is expected to grow at a double digit CAGR from 2020 to 2027 driven mainly by the rising incidence of cancer cases, lifestyle changes, increasing geriatric population, high demand for anti-cancer drugs, increase in the usage of synthetic HPAPIs for cancer treatment, increase in geriatric population and rising demand for personalized medicine especially for treating cancer.
The pharmaceutical contract manufacturing market based on region is classified into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (China, India, Japan, and Others), and the Rest of the World (Brazil, Rest of Latin America and Middle East & others). North America accounts for the largest revenue in 2020. The developed healthcare sector, availability of funds, increasing clinical trials, rising burden of cancer, increasing governments focus on generic drugs as well as the establishment of domestic API manufacturers, rising demands for the specialty of drugs and technological advancements, rising demand for advanced dosage forms, and also establishment of foreign CMOs/CDMOs are some of the factors driving the market growth. The Asia-Pacific region is the fastest growing region and is expected to grow at double digit CAGR from 2020 to 2027. Low labor cost, regulatory relaxation, abundance availability of raw materials, infrastructure facility, rise in generic demands, increased production capabilities, the presence of a large number of domestic and international players, coupled with low investments for the establishment of manufacturing facilities as compared to western countries.
Some of the major players are Lonza Group (Switzerland), AbbVie Inc. (AbbVie contract manufacturing, U.S.), Thermo Fisher Scientific (Patheon, N.V., U.S.), Pfizer Inc. (Pfizer CentreOne, U.S.), Permira Funds (Cambrex Corporation, U.K.), Carlyle Group (Albany Molecular Research Inc. U.S.), WuXi AppTec (WuXi STA pharmaceuticals, China), Recipharm AB (publ) (Sweden), Aenova Group GmbH (Germany), China Resources Pharmaceutical Group Limited (China), and others.
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
The pharmaceutical contract manufacturing global market is expected to reach $120,124.7 million by 2027 growing at a high single digit CAGR. Increased trend of outsourcing, high uptake of small molecules drugs across diverse therapeutics, patent expiration of small molecules, advanced technologies in API and FDF manufacturing, increasing deals and investments, increased demand for generic injectables, increasing incidence and prevalence of chronic diseases, and increase in geriatric population are some of the factors driving the market growth. However, contamination of pharmaceutical products (API and FDF), pricing pressure for pharmaceutical contract manufacturing, requirement of highly skilled technicians, increasing biologics approvals and adoption in disease management, stringent regulatory policies, and environmental concerns are some of the factors that are hindering pharmaceutical contract manufacturing global market growth. The pharmaceutical contract manufacturing global market is mainly segmented based on product, phase, application, and geography.
The pharmaceutical contract manufacturing market based on product is segmented into API manufacturing and FDF manufacturing. API manufacturing segment accounted for the largest share in 2020 and FDF manufacturing segment is the fastest growing segment and is expected to grow at high single digit CAGR from 2020 to 2027. The high profit margin for pharma contract manufacturers, shifting from API to FDF manufacturing by CMOs and CDMOs, rising demand for advanced dosage forms, and rising demand for generic drugs are some of the factors driving the growth of the FDF contract manufacturing market.
The API manufacturing market global market based on customer base is sub-segmented into Branded API manufacturing and Generic API manufacturing. The generic API manufacturing segment accounted for the largest revenue in 2020 and is expected to grow at high single digit CAGR from 2020 to 2027, due to the patent expiries of branded drugs, low cost of generic medicines.
The FDF manufacturing global market based on dosage form is further classified into solid dosage form, injectable dosage form, and semi-solid liquid and gaseous dosage form. Solid dosage form segment accounted for the largest revenue in 2020 due to changing consumer demands, advent and progress of newer dosage forms, and ever-evolving regulations. The injectable dosage form is the fastest-growing segment and is expected to grow at a low teen CAGR from 2020 to 2027 due to its direct infusion to the body, ease of administration, and onset of action of drugs is faster as compared to solid dosage forms. Hence it is suitable for emergency conditions. Among semi-solid, liquid, and gaseous dosage form, semisolids segment accounted for the largest revenue of in 2020 owing to the increased usage of semisolids such creams, lotions and gels due to increase in skin related diseases, and changing climatic conditions.
The solid dosage form market is further classified into tablets, capsules, and others such as powders and granules. Among these, tablets segment generated the largest revenue in 2020 owing to its ease of formulation techniques, manufacturing, and ease of administration to all the age groups.
Pharmaceutical contract manufacturing global market based on phase is segmented into commercial manufacturing and clinical manufacturing. Commercial manufacturing segment contributed to the largest revenue in 2020 due to huge demand for commercial API production, patent expiry, and increasing outsourcing of generic APIs. Whereas, clinical manufacturing segment is the fastest growing segment and is expected to grow at high single digit CAGR from 2020 to 2027 owing to a rise in demand for effective novel drugs with various therapeutic applications, rise in R&D investments for discovering new drugs coupled with the rising number of different types of chronic diseases.
The pharmaceutical contract manufacturing market by therapeutic applications is segmented into infectious diseases, oncology, cardiovascular disorders, central nervous system, pulmonary disorder, gastrointestinal disorder, endocrine disorders, metabolic disorders, genito-urinary disorders, musculoskeletal disorders, and others such as others such as ophthalmology, autoimmune diseases, ENT, dental, dermatology, and pain management. Among these applications, the infectious disease segment accounted for the largest revenue in 2020 because of the global-wide rapid spread of COVID-19 and increased incidence of other infectious diseases such as tuberculosis, HIV, pneumonia, influenza, hepatitis, and others. The oncology division is the fastest growing and is expected to grow at a double digit CAGR from 2020 to 2027 driven mainly by the rising incidence of cancer cases, lifestyle changes, increasing geriatric population, high demand for anti-cancer drugs, increase in the usage of synthetic HPAPIs for cancer treatment, increase in geriatric population and rising demand for personalized medicine especially for treating cancer.
The pharmaceutical contract manufacturing market based on region is classified into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (China, India, Japan, and Others), and the Rest of the World (Brazil, Rest of Latin America and Middle East & others). North America accounts for the largest revenue in 2020. The developed healthcare sector, availability of funds, increasing clinical trials, rising burden of cancer, increasing governments focus on generic drugs as well as the establishment of domestic API manufacturers, rising demands for the specialty of drugs and technological advancements, rising demand for advanced dosage forms, and also establishment of foreign CMOs/CDMOs are some of the factors driving the market growth. The Asia-Pacific region is the fastest growing region and is expected to grow at double digit CAGR from 2020 to 2027. Low labor cost, regulatory relaxation, abundance availability of raw materials, infrastructure facility, rise in generic demands, increased production capabilities, the presence of a large number of domestic and international players, coupled with low investments for the establishment of manufacturing facilities as compared to western countries.
Some of the major players are Lonza Group (Switzerland), AbbVie Inc. (AbbVie contract manufacturing, U.S.), Thermo Fisher Scientific (Patheon, N.V., U.S.), Pfizer Inc. (Pfizer CentreOne, U.S.), Permira Funds (Cambrex Corporation, U.K.), Carlyle Group (Albany Molecular Research Inc. U.S.), WuXi AppTec (WuXi STA pharmaceuticals, China), Recipharm AB (publ) (Sweden), Aenova Group GmbH (Germany), China Resources Pharmaceutical Group Limited (China), and others.
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
- North America
- U.S.
- Rest of North America
- Europe
- Germany
- France
- Italy
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Rest of APAC
- Rest of the World (RoW)
- Brazil
- Rest of Latin America
- Middle East and Others
1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 SCOPE OF THE REPORT
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increased trend of outsourcing
3.3.1.2 High uptake of small molecules across diverse therapeutics
3.3.1.3 Patent expiration of small molecules drugs
3.3.1.4 Advanced technologies in API and FDF manufacturing
3.3.1.5 Increasing deals and investments
3.3.1.6 Generics drive injectable market opportunity
3.3.1.7 Increasing chronic diseases
3.3.1.8 Increase in geriatric population
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Contamination in the manufacturing process (API and FDF)
3.3.2.2 Pricing pressure for pharmaceutical contract manufacturing
3.3.2.3 Requirement of highly skilled technicians
3.3.2.4 Increasing biologics approvals and adoption in disease management
3.3.2.5 Stringent regulatory requirements
3.4 REGULATORY AFFAIRS
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
3.4.1.1 ISO 9001: 2015 Quality management system
3.4.1.2 ISO 14644-1 Clean room standards
3.4.2 U.S.
3.4.3 CANADA
3.4.4 MEXICO
3.4.5 EUROPE
3.4.6 JAPAN
3.4.7 CHINA
3.4.8 INDIA
3.4.9 AUSTRALIA
3.4.10 SOUTH KOREA
3.4.11 LATIN AMERICA
3.4.12 MIDDLE EAST
3.5 PORTER’S FIVE FORCE ANALYSIS
3.5.1 THREAT OF NEW ENTRANTS
3.5.2 THREAT OF SUBSTITUTES
3.5.3 BARGAINING POWER OF SUPPLIERS
3.5.4 BARGAINING POWER OF BUYERS
3.5.5 COMPETITIVE RIVALRY
3.6 SUPPLY CHAIN ANALYSIS
3.7 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.7.1 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE ANALYSIS
3.7.2 MARKET SHARE ANALYSIS OF API MANUFACTURING BY MAJOR PLAYERS
3.7.3 MARKET SHARE ANALYSIS OF FDF MANUFACTURING BY MAJOR PLAYERS
3.8 TECHNOLOGICAL ADVANCEMENTS
3.8.1 INTRODUCTION
3.8.2 ADVANCED TECHNOLOGIES FOR API MANUFACTURING
3.8.3 ADVANCED TECHNOLOGIES FOR FDF MANUFACTURING
3.9 DIFFERENTIATED CAPABILITIES
3.9.1 HPAPI
3.9.1.1 Selected top selling HPAPI
3.9.2 CONTINUOUS FLOW MANUFACTURING
3.9.3 CRYOGENIC MANUFACTURING PROCESS
3.10 CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING MARKET
3.11 PATENT EXPIRY AND ANDA APPROVALS
3.12 DRUG MASTER FILING (DMF)
3.13 COST OF MANUFACTURING FACILITY
3.14 FDA APPROVED MANUFACTURING FACILITY
3.15 FDA AND EMA APPROVAL DRUGS WITH TYPE OF DOSAGE FORM
3.16 NOTICE OF INSPECTIONAL OBSERVATIONS (FORM 483)
3.17 IMPACT OF CORONA ON PHARMACEUTICAL CONTRACT MANUFACTURING
3.18 COLLABORATION BETWEEN PHARMACEUTICAL COMPANIES AND CONTRACT MANUFACTURERS
3.19 COMPANIES ACQUISITION, MERGER AND INVESTMENTS
3.20 API PRICING
3.21 GLOBAL PHARMACEUTICAL API CMO PRODUCTION VOLUME
3.22 CHINA V/S INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
3.22.1 INDIA
3.22.2 CHINA
3.23 PHARMACEUTICAL CONTRACT MANUFACTURERS REVENUE AND CAPABILITIES TABLE
4 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BY PRODUCT
4.1 INTRODUCTION
4.2 API MANUFACTURING
4.2.1 BRANDED API MANUFACTURING
4.2.2 GENERIC API MANUFACTURING
4.3 FINISHED DOSAGE FORM (FDF) MANUFACTURING
4.3.1 SOLID DOSAGE FORMS
4.3.1.1 Tablets
4.3.1.2 Capsules
4.3.1.3 Other solid dosage forms (Granules and Powders)
4.3.2 INJECTABLES DOSAGE FORMS
4.3.3 SEMISOLID, LIQUID AND GASEOUS DOSAGE FORMS
4.3.3.1 Semisolids
4.3.3.2 Liquids
4.3.3.3 Gaseous
5 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BY PHASE
5.1 INTRODUCTION
5.2 CLINICAL MANUFACTURING
5.3 COMMERCIAL MANUFACTURING
6 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BY APPLICATION
6.1 INTRODUCTION
6.2 ONCOLOGY
6.3 CENTRAL NERVOUS SYSTEM
6.4 CARDIOVASCULAR DISORDERS
6.5 INFECTIOUS DISEASES
6.6 PULMONARY DISORDERS
6.7 METABOLIC DISORDERS
6.8 GASTROINTESTINAL DISORDERS
6.9 MUSCULOSKELETAL DISORDERS
6.10 GENITOURINARY DISORDERS
6.11 ENDOCRINOLOGY
6.12 OTHER APPLICATIONS (ANESTHESIA, AUTOIMMUNE DISEASES, OPTHALMOLOGY, DENTAL, PAIN MANAGEMENT, GYNAECOLOGY, DERMATOLOGY, AND ENT)
7 REGIONAL ANALYSIS
7.1 INTRODUCTION
7.2 NORTH AMERICA
7.2.1 U.S.
7.2.2 REST OF NORTH AMERICA
7.3 EUROPE
7.3.1 GERMANY
7.3.2 FRANCE
7.3.3 ITALY
7.3.4 REST OF EUROPE
7.4 APAC
7.4.1 CHINA
7.4.2 INDIA
7.4.3 JAPAN
7.4.4 REST OF APAC
7.5 ROW
7.5.1 BRAZIL
7.5.2 REST OF LATAM
7.5.3 MIDDLE EAST & OTHERS
8 COMPETITIVE LANDSCAPE
8.1 INTRODUCTION
8.2 ACQUISITION
8.3 EXPANSION
8.4 AGREEMENTS
8.5 SERVICE LAUNCH AND OTHERS
9 MAJOR COMPANIES
9.1 ABBVIE INC.
9.1.1 OVERVIEW
9.1.2 FINANCIALS
9.1.3 PRODUCT PORTFOLIO
9.1.4 KEY DEVELOPMENTS
9.1.5 BUSINESS STRATEGY
9.1.6 SWOT ANALYSIS
9.2 AENOVA HOLDING GMBH
9.2.1 OVERVIEW
9.2.2 FINANCIALS
9.2.3 PRODUCT PORTFOLIO
9.2.4 KEY DEVELOPMENTS
9.2.5 BUSINESS STRATEGY
9.2.6 SWOT ANALYSIS
9.3 CARLYLE GROUP (ALBANY MOLECULAR RESEARCH INC)
9.3.1 OVERVIEW
9.3.2 FINANCIALS
9.3.3 PRODUCT PORTFOLIO
9.3.4 KEY DEVELOPMENTS
9.3.5 BUSINESS STRATEGY
9.3.6 SWOT ANALYSIS
9.4 CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED
9.4.1 OVERVIEW
9.4.2 FINANCIALS
9.4.3 PRODUCT PORTFOLIO
9.4.4 KEY DEVELOPMENTS
9.4.5 BUSINESS STRATEGY
9.4.6 SWOT ANALYSIS
9.5 FAREVA SA
9.5.1 OVERVIEW
9.5.2 FINANCIALS
9.5.3 PRODUCT PORTFOLIO
9.5.4 KEY DEVELOPMENTS
9.5.5 BUSINESS STRATEGY
9.5.6 SWOT ANALYSIS
9.6 LONZA GROUP LTD
9.6.1 OVERVIEW
9.6.2 FINANCIALS
9.6.3 PRODUCT PORTFOLIO
9.6.4 KEY DEVELOPMENTS
9.6.5 BUSINESS STRATEGY
9.6.6 SWOT ANALYSIS
9.7 PFIZER INC.
9.7.1 OVERVIEW
9.7.2 FINANCIALS
9.7.3 PRODUCT PORTFOLIO
9.7.4 KEY DEVELOPMENTS
9.7.5 BUSINESS STRATEGY
9.7.6 SWOT ANALYSIS
9.8 PERMIRA FUNDS (CAMBREX CORPORATION U.K.) CORPORATION
9.8.1 OVERVIEW
9.8.2 FINANCIALS
9.8.3 PRODUCT PORTFOLIO
9.8.4 KEY DEVELOPMENTS
9.8.5 BUSINESS STRATEGY
9.8.6 SWOT ANALYSIS
9.9 RECIPHARM AB
9.9.1 OVERVIEW
9.9.2 FINANCIALS
9.9.3 PRODUCT PORTFOLIO
9.9.4 KEY DEVELOPMENTS
9.9.5 BUSINESS STRATEGY
9.9.6 SWOT ANALYSIS
9.10 THERMO FISHER SCIENTIFIC INC
9.10.1 OVERVIEW
9.10.2 FINANCIALS
9.10.3 PRODUCT PORTFOLIO
9.10.4 KEY DEVELOPMENTS
9.10.5 BUSINESS STRATEGY
9.10.6 SWOT ANALYSIS
9.11 WUXI APPTEC (WUXI STA PHARMACEUTICALS LTD)
9.11.1 OVERVIEW
9.11.2 FINANCIALS
9.11.3 PRODUCT PORTFOLIO
9.11.4 KEY DEVELOPMENTS
9.11.5 BUSINESS STRATEGY
9.11.6 SWOT ANALYSIS
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 SCOPE OF THE REPORT
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increased trend of outsourcing
3.3.1.2 High uptake of small molecules across diverse therapeutics
3.3.1.3 Patent expiration of small molecules drugs
3.3.1.4 Advanced technologies in API and FDF manufacturing
3.3.1.5 Increasing deals and investments
3.3.1.6 Generics drive injectable market opportunity
3.3.1.7 Increasing chronic diseases
3.3.1.8 Increase in geriatric population
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Contamination in the manufacturing process (API and FDF)
3.3.2.2 Pricing pressure for pharmaceutical contract manufacturing
3.3.2.3 Requirement of highly skilled technicians
3.3.2.4 Increasing biologics approvals and adoption in disease management
3.3.2.5 Stringent regulatory requirements
3.4 REGULATORY AFFAIRS
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
3.4.1.1 ISO 9001: 2015 Quality management system
3.4.1.2 ISO 14644-1 Clean room standards
3.4.2 U.S.
3.4.3 CANADA
3.4.4 MEXICO
3.4.5 EUROPE
3.4.6 JAPAN
3.4.7 CHINA
3.4.8 INDIA
3.4.9 AUSTRALIA
3.4.10 SOUTH KOREA
3.4.11 LATIN AMERICA
3.4.12 MIDDLE EAST
3.5 PORTER’S FIVE FORCE ANALYSIS
3.5.1 THREAT OF NEW ENTRANTS
3.5.2 THREAT OF SUBSTITUTES
3.5.3 BARGAINING POWER OF SUPPLIERS
3.5.4 BARGAINING POWER OF BUYERS
3.5.5 COMPETITIVE RIVALRY
3.6 SUPPLY CHAIN ANALYSIS
3.7 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.7.1 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE ANALYSIS
3.7.2 MARKET SHARE ANALYSIS OF API MANUFACTURING BY MAJOR PLAYERS
3.7.3 MARKET SHARE ANALYSIS OF FDF MANUFACTURING BY MAJOR PLAYERS
3.8 TECHNOLOGICAL ADVANCEMENTS
3.8.1 INTRODUCTION
3.8.2 ADVANCED TECHNOLOGIES FOR API MANUFACTURING
3.8.3 ADVANCED TECHNOLOGIES FOR FDF MANUFACTURING
3.9 DIFFERENTIATED CAPABILITIES
3.9.1 HPAPI
3.9.1.1 Selected top selling HPAPI
3.9.2 CONTINUOUS FLOW MANUFACTURING
3.9.3 CRYOGENIC MANUFACTURING PROCESS
3.10 CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING MARKET
3.11 PATENT EXPIRY AND ANDA APPROVALS
3.12 DRUG MASTER FILING (DMF)
3.13 COST OF MANUFACTURING FACILITY
3.14 FDA APPROVED MANUFACTURING FACILITY
3.15 FDA AND EMA APPROVAL DRUGS WITH TYPE OF DOSAGE FORM
3.16 NOTICE OF INSPECTIONAL OBSERVATIONS (FORM 483)
3.17 IMPACT OF CORONA ON PHARMACEUTICAL CONTRACT MANUFACTURING
3.18 COLLABORATION BETWEEN PHARMACEUTICAL COMPANIES AND CONTRACT MANUFACTURERS
3.19 COMPANIES ACQUISITION, MERGER AND INVESTMENTS
3.20 API PRICING
3.21 GLOBAL PHARMACEUTICAL API CMO PRODUCTION VOLUME
3.22 CHINA V/S INDIA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
3.22.1 INDIA
3.22.2 CHINA
3.23 PHARMACEUTICAL CONTRACT MANUFACTURERS REVENUE AND CAPABILITIES TABLE
4 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BY PRODUCT
4.1 INTRODUCTION
4.2 API MANUFACTURING
4.2.1 BRANDED API MANUFACTURING
4.2.2 GENERIC API MANUFACTURING
4.3 FINISHED DOSAGE FORM (FDF) MANUFACTURING
4.3.1 SOLID DOSAGE FORMS
4.3.1.1 Tablets
4.3.1.2 Capsules
4.3.1.3 Other solid dosage forms (Granules and Powders)
4.3.2 INJECTABLES DOSAGE FORMS
4.3.3 SEMISOLID, LIQUID AND GASEOUS DOSAGE FORMS
4.3.3.1 Semisolids
4.3.3.2 Liquids
4.3.3.3 Gaseous
5 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BY PHASE
5.1 INTRODUCTION
5.2 CLINICAL MANUFACTURING
5.3 COMMERCIAL MANUFACTURING
6 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET, BY APPLICATION
6.1 INTRODUCTION
6.2 ONCOLOGY
6.3 CENTRAL NERVOUS SYSTEM
6.4 CARDIOVASCULAR DISORDERS
6.5 INFECTIOUS DISEASES
6.6 PULMONARY DISORDERS
6.7 METABOLIC DISORDERS
6.8 GASTROINTESTINAL DISORDERS
6.9 MUSCULOSKELETAL DISORDERS
6.10 GENITOURINARY DISORDERS
6.11 ENDOCRINOLOGY
6.12 OTHER APPLICATIONS (ANESTHESIA, AUTOIMMUNE DISEASES, OPTHALMOLOGY, DENTAL, PAIN MANAGEMENT, GYNAECOLOGY, DERMATOLOGY, AND ENT)
7 REGIONAL ANALYSIS
7.1 INTRODUCTION
7.2 NORTH AMERICA
7.2.1 U.S.
7.2.2 REST OF NORTH AMERICA
7.3 EUROPE
7.3.1 GERMANY
7.3.2 FRANCE
7.3.3 ITALY
7.3.4 REST OF EUROPE
7.4 APAC
7.4.1 CHINA
7.4.2 INDIA
7.4.3 JAPAN
7.4.4 REST OF APAC
7.5 ROW
7.5.1 BRAZIL
7.5.2 REST OF LATAM
7.5.3 MIDDLE EAST & OTHERS
8 COMPETITIVE LANDSCAPE
8.1 INTRODUCTION
8.2 ACQUISITION
8.3 EXPANSION
8.4 AGREEMENTS
8.5 SERVICE LAUNCH AND OTHERS
9 MAJOR COMPANIES
9.1 ABBVIE INC.
9.1.1 OVERVIEW
9.1.2 FINANCIALS
9.1.3 PRODUCT PORTFOLIO
9.1.4 KEY DEVELOPMENTS
9.1.5 BUSINESS STRATEGY
9.1.6 SWOT ANALYSIS
9.2 AENOVA HOLDING GMBH
9.2.1 OVERVIEW
9.2.2 FINANCIALS
9.2.3 PRODUCT PORTFOLIO
9.2.4 KEY DEVELOPMENTS
9.2.5 BUSINESS STRATEGY
9.2.6 SWOT ANALYSIS
9.3 CARLYLE GROUP (ALBANY MOLECULAR RESEARCH INC)
9.3.1 OVERVIEW
9.3.2 FINANCIALS
9.3.3 PRODUCT PORTFOLIO
9.3.4 KEY DEVELOPMENTS
9.3.5 BUSINESS STRATEGY
9.3.6 SWOT ANALYSIS
9.4 CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED
9.4.1 OVERVIEW
9.4.2 FINANCIALS
9.4.3 PRODUCT PORTFOLIO
9.4.4 KEY DEVELOPMENTS
9.4.5 BUSINESS STRATEGY
9.4.6 SWOT ANALYSIS
9.5 FAREVA SA
9.5.1 OVERVIEW
9.5.2 FINANCIALS
9.5.3 PRODUCT PORTFOLIO
9.5.4 KEY DEVELOPMENTS
9.5.5 BUSINESS STRATEGY
9.5.6 SWOT ANALYSIS
9.6 LONZA GROUP LTD
9.6.1 OVERVIEW
9.6.2 FINANCIALS
9.6.3 PRODUCT PORTFOLIO
9.6.4 KEY DEVELOPMENTS
9.6.5 BUSINESS STRATEGY
9.6.6 SWOT ANALYSIS
9.7 PFIZER INC.
9.7.1 OVERVIEW
9.7.2 FINANCIALS
9.7.3 PRODUCT PORTFOLIO
9.7.4 KEY DEVELOPMENTS
9.7.5 BUSINESS STRATEGY
9.7.6 SWOT ANALYSIS
9.8 PERMIRA FUNDS (CAMBREX CORPORATION U.K.) CORPORATION
9.8.1 OVERVIEW
9.8.2 FINANCIALS
9.8.3 PRODUCT PORTFOLIO
9.8.4 KEY DEVELOPMENTS
9.8.5 BUSINESS STRATEGY
9.8.6 SWOT ANALYSIS
9.9 RECIPHARM AB
9.9.1 OVERVIEW
9.9.2 FINANCIALS
9.9.3 PRODUCT PORTFOLIO
9.9.4 KEY DEVELOPMENTS
9.9.5 BUSINESS STRATEGY
9.9.6 SWOT ANALYSIS
9.10 THERMO FISHER SCIENTIFIC INC
9.10.1 OVERVIEW
9.10.2 FINANCIALS
9.10.3 PRODUCT PORTFOLIO
9.10.4 KEY DEVELOPMENTS
9.10.5 BUSINESS STRATEGY
9.10.6 SWOT ANALYSIS
9.11 WUXI APPTEC (WUXI STA PHARMACEUTICALS LTD)
9.11.1 OVERVIEW
9.11.2 FINANCIALS
9.11.3 PRODUCT PORTFOLIO
9.11.4 KEY DEVELOPMENTS
9.11.5 BUSINESS STRATEGY
9.11.6 SWOT ANALYSIS
LIST OF TABLES
TABLE 1 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 2 CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING REVENUE, BY MARKET, (2019-2027) ($MN)
TABLE 3 PATENT EXPIRY OF SMALL MOLECULE DRUGS, (2018 – 2025)
TABLE 4 ANDA APPROVALS, (2020 – 2021)
TABLE 5 AGREEMENTS/PARTNERSHIP, (2019 – 2021)
TABLE 6 ACQUISITION AND MERGER, (2019 – 2021)
TABLE 7 INVESTEMENTS, (2019 – 2021)
TABLE 8 API PRICING OF MAJOR SMALL MOLECULES
TABLE 9 GLOBAL PHARMACEUTICALS API REVENUE ($MN), AVERAGE SELLING PRICE ($/KG) AND PRODUCTION IN TONS, BY APPLICATION (2020)
TABLE 10 GLOBAL PHARMACEUTICAL API PRODUCTION, BY APPLICATION, (2019-2027) (TONS)
TABLE 11 GLOBAL SMALL MOLECULE API PRODUCTION, (2019 -2027) (METRIC TONS)
TABLE 12 GLOBAL PHARMACEUTICAL VOLUME AND UTILIZATION, CMO VOLUME AND UTILIZATION, (2019-2027) (MILLION LITRES)
TABLE 13 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY PRODUCT (2019-2027) ($MN)
TABLE 14 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 15 API MANUFACTURING GLOBAL MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
TABLE 16 API MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 17 BRANDED API MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 18 GENERIC API MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 19 FDF MANUFACTURING GLOBAL MARKET REVENUE, BY DOSAGE FORM, (2019-2027) ($MN)
TABLE 20 FDF MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 21 SOLID DOSAGE FORMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 22 INJECTABLES DOSAGE FORMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 23 SEMISOLID, LIQUID AND GASEOUS DOSAGE FORMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 24 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY PHASE, (2019-2027) ($MN)
TABLE 25 CLINICAL MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 26 COMMERCIAL MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 27 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 28 ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 29 CENTRAL NERVOUS SYSTEM GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 30 CARDIOVASCULAR DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 31 INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 32 PULMONARY DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 33 METABOLIC DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 34 GASTROINTESTINAL DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 35 MUSCULOSKELETAL DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 36 GENITOURINARY DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 37 ENDOCRINOLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 38 OTHER APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 39 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 40 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 41 NORTH AMERICA API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
TABLE 42 NORTH AMERICA FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2019-2027) ($MN)
TABLE 43 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2019-2027) ($MN)
TABLE 44 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 45 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 46 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 47 EUROPE API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
TABLE 48 EUROPE FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2019-2027) ($MN)
TABLE 49 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2019-2027) ($MN)
TABLE 50 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 51 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 52 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 53 APAC API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
TABLE 54 APAC FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2019-2027) ($MN)
TABLE 55 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2019-2027) ($MN)
TABLE 56 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 57 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 58 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 59 ROW API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
TABLE 60 ROW FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2019-2027) ($MN)
TABLE 61 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2019-2027) ($MN)
TABLE 62 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 63 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 64 ACQUISITION (2019-2021)
TABLE 65 EXPANSION (2019-2021)
TABLE 66 AGREEMENTS (2019-2021)
TABLE 67 SERVICE LAUNCH AND OTHERS (2019-2021)
TABLE 68 ABBVIE INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 69 ABBVIE INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 70 AENOVA HOLDING GMBH: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 71 CHINA RESOURCES PHARMACEUTICALS GROUP LIMITED: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 72 CHINA RESOURCES PHARMACEUTICALS GROUP LIMITED: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 73 LONZA GROUP: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 74 LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 75 LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 76 PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, (2018-2019) ($MN)
TABLE 77 PFIZER INC: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
TABLE 78 PFIZER INC: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 79 RECIPHARM AB (PUBL): TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN)
TABLE 80 RECIPHARM AB (PUBL): TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 81 RECIPHARM AB (PUBL): TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 82 THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 83 THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 84 THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 85 WUXI APPTEC: TOTAL REVENUE & R&D EXPENSES (2018 -2020) ($MN)
TABLE 86 WUXI APPTEC: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 1 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 2 CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING REVENUE, BY MARKET, (2019-2027) ($MN)
TABLE 3 PATENT EXPIRY OF SMALL MOLECULE DRUGS, (2018 – 2025)
TABLE 4 ANDA APPROVALS, (2020 – 2021)
TABLE 5 AGREEMENTS/PARTNERSHIP, (2019 – 2021)
TABLE 6 ACQUISITION AND MERGER, (2019 – 2021)
TABLE 7 INVESTEMENTS, (2019 – 2021)
TABLE 8 API PRICING OF MAJOR SMALL MOLECULES
TABLE 9 GLOBAL PHARMACEUTICALS API REVENUE ($MN), AVERAGE SELLING PRICE ($/KG) AND PRODUCTION IN TONS, BY APPLICATION (2020)
TABLE 10 GLOBAL PHARMACEUTICAL API PRODUCTION, BY APPLICATION, (2019-2027) (TONS)
TABLE 11 GLOBAL SMALL MOLECULE API PRODUCTION, (2019 -2027) (METRIC TONS)
TABLE 12 GLOBAL PHARMACEUTICAL VOLUME AND UTILIZATION, CMO VOLUME AND UTILIZATION, (2019-2027) (MILLION LITRES)
TABLE 13 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY PRODUCT (2019-2027) ($MN)
TABLE 14 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 15 API MANUFACTURING GLOBAL MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
TABLE 16 API MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 17 BRANDED API MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 18 GENERIC API MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 19 FDF MANUFACTURING GLOBAL MARKET REVENUE, BY DOSAGE FORM, (2019-2027) ($MN)
TABLE 20 FDF MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 21 SOLID DOSAGE FORMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 22 INJECTABLES DOSAGE FORMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 23 SEMISOLID, LIQUID AND GASEOUS DOSAGE FORMS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 24 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY PHASE, (2019-2027) ($MN)
TABLE 25 CLINICAL MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 26 COMMERCIAL MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 27 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 28 ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 29 CENTRAL NERVOUS SYSTEM GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 30 CARDIOVASCULAR DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 31 INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 32 PULMONARY DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 33 METABOLIC DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 34 GASTROINTESTINAL DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 35 MUSCULOSKELETAL DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 36 GENITOURINARY DISORDERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 37 ENDOCRINOLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 38 OTHER APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 39 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 40 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 41 NORTH AMERICA API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
TABLE 42 NORTH AMERICA FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2019-2027) ($MN)
TABLE 43 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2019-2027) ($MN)
TABLE 44 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 45 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 46 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 47 EUROPE API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
TABLE 48 EUROPE FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2019-2027) ($MN)
TABLE 49 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2019-2027) ($MN)
TABLE 50 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 51 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 52 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 53 APAC API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
TABLE 54 APAC FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2019-2027) ($MN)
TABLE 55 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2019-2027) ($MN)
TABLE 56 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 57 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 58 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 59 ROW API MANUFACTURING MARKET REVENUE, BY CUSTOMER BASE, (2019-2027) ($MN)
TABLE 60 ROW FDF MANUFACTURING MARKET REVENUE, BY DOSAGE FORM, (2019-2027) ($MN)
TABLE 61 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PHASE, (2019-2027) ($MN)
TABLE 62 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
TABLE 63 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 64 ACQUISITION (2019-2021)
TABLE 65 EXPANSION (2019-2021)
TABLE 66 AGREEMENTS (2019-2021)
TABLE 67 SERVICE LAUNCH AND OTHERS (2019-2021)
TABLE 68 ABBVIE INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 69 ABBVIE INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 70 AENOVA HOLDING GMBH: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 71 CHINA RESOURCES PHARMACEUTICALS GROUP LIMITED: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 72 CHINA RESOURCES PHARMACEUTICALS GROUP LIMITED: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 73 LONZA GROUP: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 74 LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 75 LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 76 PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, (2018-2019) ($MN)
TABLE 77 PFIZER INC: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
TABLE 78 PFIZER INC: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 79 RECIPHARM AB (PUBL): TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN)
TABLE 80 RECIPHARM AB (PUBL): TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 81 RECIPHARM AB (PUBL): TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 82 THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
TABLE 83 THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
TABLE 84 THERMO FISHER SCIENTIFIC INC: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
TABLE 85 WUXI APPTEC: TOTAL REVENUE & R&D EXPENSES (2018 -2020) ($MN)
TABLE 86 WUXI APPTEC: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
LIST OF FIGURES
FIGURE 1 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET
FIGURE 3 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SEGMENTATION
FIGURE 7 MARKET DYNAMICS
FIGURE 8 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 9 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 10 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 11 API MANUFACTURING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 12 FDF MANUFACTURING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 13 CONTRACT MANUFACTURING COMPANY CAPABILITIES
FIGURE 14 CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING REVENUE, BY MARKET, 2020 ($MN)
FIGURE 15 PATENT EXPIRY OF SMALL MOLECULES (2018-2025)
FIGURE 16 PATENT EXPIRY (2018-2025) AND ANDA APPROVALS (2020-2021), BY APPLICATION SHARE (%)
FIGURE 17 API DMF FILED BY COUNTRIES (2020) (NO’S)
FIGURE 18 API DMF FILED, BY COMPANY (2020) (NO’S)
FIGURE 19 FDA APPROVED GLOBAL API MANUFACTURING LANDSCAPE (2020)
FIGURE 20 FDA AND EMA APPROVED DRUGS AND FORMULATION TYPE (2020 – 2021)
FIGURE 21 FORM 483 NON-COMPLIANCE, BY COUNTRY (2020) (NO’S)
FIGURE 22 PHARMACEUTICAL API PRODUCTION BY APPLICATION (2020), IN-HOUSE V/S CMO (2019 – 2027) (TONS) AND GLOBAL MANUFACTURING CAPACITIES (2020) (LITRES)
FIGURE 23 GLOBAL PHARMACEUTICAL API CMO PRODUCTION (2019 – 2027) (TONS), API CMO MARKET SHARE BY REGION (2020) (%)
FIGURE 24 INDIA V/S CHINA
FIGURE 25 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
FIGURE 26 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 27 API MANUFACTURING GLOBAL MARKET SHARE, BY CUSTOMER BASE (2020 V/S 2027) (%)
FIGURE 28 FDF MANUFACTURING GLOBAL MARKET SHARE, BY DOSAGE FORM, (2020 V/S 2027) (%)
FIGURE 29 SOLID DOSAGE FORM CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY DOSAGE TYPE, (2020) (%)
FIGURE 30 SEMI-SOLID, LIQUID, AND GASEOUS DOSAGE FORM CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY DOSAGE FORM, (2020) (%)
FIGURE 31 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY PHASE (2020 V/S 2027) (%)
FIGURE 32 COMMERCIAL MANUFACTURING GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
FIGURE 33 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
FIGURE 34 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN), CAGR (%)
FIGURE 35 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY GEOGRAPHY (2020) (%)
FIGURE 36 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT AND BY PHASE (2020 V/S 2027) (%)
FIGURE 37 NORTH AMERICA PHARMACEUTICAL CONTRACT API AND FDF MANUFACTURING MARKET SHARE, BY CUSTOMER BASE AND BY DOSAGE FORM (2020 V/S 2027) (%)
FIGURE 38 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
FIGURE 39 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 40 U.S. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 41 U.S. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
FIGURE 42 REST OF NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 43 REST OF NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
FIGURE 44 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT AND BY PHASE (2020 V/S 2027) (%)
FIGURE 45 EUROPE PHARMACEUTICAL CONTRACT API AND FDF MANUFACTURING MARKET SHARE, BY CUSTOMER PHASE AND BY DOSAGE FORM (2020 V/S 2027) (%)
FIGURE 46 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
FIGURE 47 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 48 GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 49 GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 50 FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 51 FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 52 ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 53 ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 54 REST OF EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 55 REST OF EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 56 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT AND BY PHASE (2020 V/S 2027) (%)
FIGURE 57 APAC PHARMACEUTICAL CONTRACT API AND FDF MANUFACTURING MARKET SHARE BY CUSTOMER BASE AND DOSAGE FORM (2020 V/S 2027) (%)
FIGURE 58 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2020 VS 2027) (%)
FIGURE 59 APAC PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 60 CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 61 CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 62 INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 63 INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 64 JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 65 JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 66 REST OF APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 67 REST OF APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 68 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT, BY PHASE (2020 V/S 2027) (%)
FIGURE 69 ROW PHARMACEUTICAL CONTRACT API AND FDF MANUFACTURING MARKET BY CUSTOMER BASE AND BY DOSAGE FORMS (2020 V/S 2027) (%)
FIGURE 70 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2020) (%)
FIGURE 71 ROW PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 72 BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 73 BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 74 REST OF LATAM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 75 REST OF LATAM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 76 MIDDLE EAST & OTHERS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 77 MIDDLE EAST & OTHERS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 78 KEY GROWTH STRATEGIES, (2019-2021)
FIGURE 79 SWOT: ABBVIE INC.
FIGURE 80 SWOT: AENOVA HOLDING GMBH
FIGURE 81 SWOT: CARLYLE GROUP (ALBANY MOLECULAR RESEARCH INC)
FIGURE 82 SWOT: CHINA RESOURCES PHARMACEUTICALS GROUP LIMITED
FIGURE 83 SWOT: FAREVA
FIGURE 84 SWOT: LONZA GROUP
FIGURE 85 SWOT: PFIZER INC.
FIGURE 86 SWOT: PREMIRA FUNDS (CAMBREX CORPORATION U.K.) CORPORATION
FIGURE 87 SWOT: RECIPHARM AB (PUBL)
FIGURE 88 SWOT: THERMO FISHER SCIENTIFIC
FIGURE 89 SWOT: WUXI APPTEC (WUXI STA PHARMACEUTICALS LTD)
FIGURE 1 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET
FIGURE 3 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SEGMENTATION
FIGURE 7 MARKET DYNAMICS
FIGURE 8 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 9 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 10 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 11 API MANUFACTURING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 12 FDF MANUFACTURING GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 13 CONTRACT MANUFACTURING COMPANY CAPABILITIES
FIGURE 14 CONTROLLED SUBSTANCE API CONTRACT MANUFACTURING REVENUE, BY MARKET, 2020 ($MN)
FIGURE 15 PATENT EXPIRY OF SMALL MOLECULES (2018-2025)
FIGURE 16 PATENT EXPIRY (2018-2025) AND ANDA APPROVALS (2020-2021), BY APPLICATION SHARE (%)
FIGURE 17 API DMF FILED BY COUNTRIES (2020) (NO’S)
FIGURE 18 API DMF FILED, BY COMPANY (2020) (NO’S)
FIGURE 19 FDA APPROVED GLOBAL API MANUFACTURING LANDSCAPE (2020)
FIGURE 20 FDA AND EMA APPROVED DRUGS AND FORMULATION TYPE (2020 – 2021)
FIGURE 21 FORM 483 NON-COMPLIANCE, BY COUNTRY (2020) (NO’S)
FIGURE 22 PHARMACEUTICAL API PRODUCTION BY APPLICATION (2020), IN-HOUSE V/S CMO (2019 – 2027) (TONS) AND GLOBAL MANUFACTURING CAPACITIES (2020) (LITRES)
FIGURE 23 GLOBAL PHARMACEUTICAL API CMO PRODUCTION (2019 – 2027) (TONS), API CMO MARKET SHARE BY REGION (2020) (%)
FIGURE 24 INDIA V/S CHINA
FIGURE 25 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
FIGURE 26 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%)
FIGURE 27 API MANUFACTURING GLOBAL MARKET SHARE, BY CUSTOMER BASE (2020 V/S 2027) (%)
FIGURE 28 FDF MANUFACTURING GLOBAL MARKET SHARE, BY DOSAGE FORM, (2020 V/S 2027) (%)
FIGURE 29 SOLID DOSAGE FORM CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY DOSAGE TYPE, (2020) (%)
FIGURE 30 SEMI-SOLID, LIQUID, AND GASEOUS DOSAGE FORM CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY DOSAGE FORM, (2020) (%)
FIGURE 31 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY PHASE (2020 V/S 2027) (%)
FIGURE 32 COMMERCIAL MANUFACTURING GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
FIGURE 33 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
FIGURE 34 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN), CAGR (%)
FIGURE 35 PHARMACEUTICAL CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY GEOGRAPHY (2020) (%)
FIGURE 36 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT AND BY PHASE (2020 V/S 2027) (%)
FIGURE 37 NORTH AMERICA PHARMACEUTICAL CONTRACT API AND FDF MANUFACTURING MARKET SHARE, BY CUSTOMER BASE AND BY DOSAGE FORM (2020 V/S 2027) (%)
FIGURE 38 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
FIGURE 39 NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 40 U.S. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 41 U.S. PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
FIGURE 42 REST OF NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 43 REST OF NORTH AMERICA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
FIGURE 44 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT AND BY PHASE (2020 V/S 2027) (%)
FIGURE 45 EUROPE PHARMACEUTICAL CONTRACT API AND FDF MANUFACTURING MARKET SHARE, BY CUSTOMER PHASE AND BY DOSAGE FORM (2020 V/S 2027) (%)
FIGURE 46 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%)
FIGURE 47 EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 48 GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 49 GERMANY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 50 FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 51 FRANCE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 52 ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 53 ITALY PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 54 REST OF EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 55 REST OF EUROPE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 56 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT AND BY PHASE (2020 V/S 2027) (%)
FIGURE 57 APAC PHARMACEUTICAL CONTRACT API AND FDF MANUFACTURING MARKET SHARE BY CUSTOMER BASE AND DOSAGE FORM (2020 V/S 2027) (%)
FIGURE 58 APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2020 VS 2027) (%)
FIGURE 59 APAC PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 60 CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 61 CHINA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 62 INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 63 INDIA PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 64 JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 65 JAPAN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 66 REST OF APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 67 REST OF APAC PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 68 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY PRODUCT, BY PHASE (2020 V/S 2027) (%)
FIGURE 69 ROW PHARMACEUTICAL CONTRACT API AND FDF MANUFACTURING MARKET BY CUSTOMER BASE AND BY DOSAGE FORMS (2020 V/S 2027) (%)
FIGURE 70 ROW PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE, BY APPLICATION (2020) (%)
FIGURE 71 ROW PHARMACEUTICAL CONTRACT MANUFACTURING SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 72 BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 73 BRAZIL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 74 REST OF LATAM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 75 REST OF LATAM PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 76 MIDDLE EAST & OTHERS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY PRODUCT (2020 V/S 2027) ($MN)
FIGURE 77 MIDDLE EAST & OTHERS PHARMACEUTICAL CONTRACT MANUFACTURING MARKET REVENUE, BY APPLICATION (2020 VS 2027) ($MN)
FIGURE 78 KEY GROWTH STRATEGIES, (2019-2021)
FIGURE 79 SWOT: ABBVIE INC.
FIGURE 80 SWOT: AENOVA HOLDING GMBH
FIGURE 81 SWOT: CARLYLE GROUP (ALBANY MOLECULAR RESEARCH INC)
FIGURE 82 SWOT: CHINA RESOURCES PHARMACEUTICALS GROUP LIMITED
FIGURE 83 SWOT: FAREVA
FIGURE 84 SWOT: LONZA GROUP
FIGURE 85 SWOT: PFIZER INC.
FIGURE 86 SWOT: PREMIRA FUNDS (CAMBREX CORPORATION U.K.) CORPORATION
FIGURE 87 SWOT: RECIPHARM AB (PUBL)
FIGURE 88 SWOT: THERMO FISHER SCIENTIFIC
FIGURE 89 SWOT: WUXI APPTEC (WUXI STA PHARMACEUTICALS LTD)
